Dual Therapy With Dabigatran/Ticagrelor Versus Dual Therapy With Dabigatran/Clopidogrel in ACS Patients With Indication for NOAC Undergoing PCI

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 1000 participants.

Also called NCT04688723

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 1,000 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04688723
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Netherlands (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04688723. Randomized; no masking; primary purpose treatment. Start 2020-12-23 (actual); primary completion 2022-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Dual Therapy With Dabigatran/Ticagrelor Versus Dual Therapy With Dabigatran/Clopidogrel in ACS Patients With Indication for NOAC Undergoing PCI
Acronym
RE-DUAL PCI
Condition
Myocardial Ischemia
Intervention (Drug)
Dabigatran + Ticagrelor
Intervention (Drug)
Dabigatran + clopidogrel
Lead sponsor
Zuyderland Medisch Centrum (class: other)
Collaborator
Boehringer Ingelheim (class: industry)

Record details

Record id
cardio:ct-nct04688723
Content hash
baaf9b5c081a43c45d66292a75d795233cdd8d8b44b7647bb6c6b17f266e0de5